Form 4: Organogenesis CFO David Francisco Receives Stock and Option Grants

Chief Financial Officer David Francisco of Organogenesis Holdings Inc. reports the acquisition of restricted stock units and stock options.

Summary

• David Francisco, CFO of Organogenesis Holdings Inc., filed a Form 4 detailing changes in beneficial ownership.
• On February 19, 2025, Francisco acquired 165,156 shares of Class A Common Stock through a grant of restricted stock units (RSUs).
• These RSUs vest in equal annual installments over four years, starting February 15, 2025.
• Francisco also acquired options to purchase 170,841 shares of Class A Common Stock at an exercise price of $3.53.
• These options become exercisable in equal annual installments over four years, also beginning February 15, 2025.
• Following these transactions, Francisco beneficially owns 559,095 shares of Class A Common Stock and options for 170,841 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning management interests with shareholders through equity ownership.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and exercisability schedules of the granted securities.

Industry Context

Stock and option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Vesting schedules, such as the four-year annual vesting described in the document, are typical to ensure long-term alignment of executive and shareholder interests.
• Comparing the size of the grant to similar companies in the regenerative medicine space would require further analysis of executive compensation data for peer companies.

Stakeholder Impact

• The grants aim to align the CFO's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Organogenesis Holdings Inc., David Francisco, CFO, Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, ORGO